Several other equities analysts have also recently weighed in on PRPH. TheStreet cut shares of ProPhase Labs from a b- rating to a c+ rating in a research report on Tuesday, May 17th. HC Wainwright dropped their price target on shares of ProPhase Labs from $16.00 to $14.00 and set a buy rating on the stock in a research report on Monday, May 16th. Finally, Zacks Investment Research raised shares of ProPhase Labs from a hold rating to a buy rating and set a $7.75 price target on the stock in a research report on Tuesday, February 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $10.88.
Shares of PRPH opened at $8.35 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.67 and a quick ratio of 3.65. The stock has a 50-day moving average of $7.43 and a 200-day moving average of $7.01. The company has a market cap of $129.31 million and a PE ratio of 8.27. ProPhase Labs has a one year low of $4.44 and a one year high of $8.58.
Several large investors have recently bought and sold shares of the stock. State Street Corp raised its holdings in shares of ProPhase Labs by 14.2% in the 1st quarter. State Street Corp now owns 31,063 shares of the company’s stock worth $217,000 after purchasing an additional 3,868 shares during the period. Vanguard Group Inc. grew its stake in ProPhase Labs by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 512,609 shares of the company’s stock valued at $3,588,000 after buying an additional 14,671 shares in the last quarter. Avidian Wealth Solutions LLC grew its stake in ProPhase Labs by 17.2% in the 1st quarter. Avidian Wealth Solutions LLC now owns 140,342 shares of the company’s stock valued at $982,000 after buying an additional 20,588 shares in the last quarter. Marshall Wace LLP purchased a new position in ProPhase Labs in the 3rd quarter valued at approximately $119,000. Finally, HighVista Strategies LLC purchased a new position in ProPhase Labs in the 3rd quarter valued at approximately $105,000. 9.75% of the stock is currently owned by institutional investors.
ProPhase Labs Company Profile (Get Rating)
ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
- Get a free copy of the StockNews.com research report on ProPhase Labs (PRPH)
- Zoom Video Communications Is Primed To Launch Higher
- Institutions Buy The Dip In Petco Health and Wellness Company
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Veeva Systems: Increasing NDR and Other Wins
- Autozone Edges Past Advanced Auto Parts In Q1 2022
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.